Search Results for: MET

Novel Interactant Symbol Name
Associated Pathways
Binding Drugs
Associated Diseases
Novel ABL2 ABL proto-oncogene 2, non-receptor tyrosine kinase
  • Role of ABL in ROBO-SLIT signaling
  • Role of ABL in ROBO-SLIT signaling
  • RAC1 GTPase cycle
  • RAC3 GTPase cycle
  • Negative regulation of FLT3
  • ATP
  • Dasatinib
  • XL228
  • K-00546
  • Fostamatinib
Novel BAG1 BAG cochaperone 1
  • Regulation of HSF1-mediated heat shock response
  • (2R,3R,4S,5R)-2-[6-amino-8-[(3,4-dichlorophenyl)methylamino]purin-9-yl]-5-(hydroxymethyl)oxolane-3,4-diol
Novel BCAR3 BCAR3 adaptor protein, NSP family member
Novel BLK BLK proto-oncogene, Src family tyrosine kinase
  • RUNX1 regulates transcription of genes involved in BCR signaling
  • Antigen activates B Cell Receptor (BCR) leading to generation of second messengers
  • Fostamatinib
  • Zanubrutinib
  • Maturity onset diabetes of the young (MODY)
Novel BTK Bruton tyrosine kinase
  • ER-Phagosome pathway
  • MyD88:MAL(TIRAP) cascade initiated on plasma membrane
  • Regulation of actin dynamics for phagocytic cup formation
  • DAP12 signaling
  • FCERI mediated Ca+2 mobilization
  • FCERI mediated Ca+2 mobilization
  • G alpha (q) signalling events
  • G alpha (12/13) signalling events
  • MyD88 deficiency (TLR2/4)
  • IRAK4 deficiency (TLR2/4)
  • RHO GTPases Activate WASPs and WAVEs
  • G beta:gamma signalling through BTK
  • FCGR3A-mediated phagocytosis
  • Potential therapeutics for SARS
  • Antigen activates B Cell Receptor (BCR) leading to generation of second messengers
  • Antigen activates B Cell Receptor (BCR) leading to generation of second messengers
  • Dasatinib
  • Inositol 1,3,4,5-Tetrakisphosphate
  • XL418
  • Ibrutinib
  • Acalabrutinib
  • Spebrutinib
  • Fostamatinib
  • Fenebrutinib
  • Zanubrutinib
  • Evobrutinib
  • Tirabrutinib
  • Abivertinib
  • Branebrutinib
  • Vecabrutinib
  • Pituitary Dwarfism (PD); Isolated growth hormone deficiency (IGHD); Short Stature and Pituitary Defects (SSPD); Insulin-like growth factor 1 deficiency (IGFD)
  • Agammaglobulinemias, including the following six diseases: X-linked agammaglobulinemia (Bruton's agammaglobulinemia, XLA); IgM heavy chain gene deletions; Ig-alpha defect; Autosomal recessive agammaglobulinaemia; B cell-linker protein (BLNK) deficiency; Leucine-rich repeat-containing 8
Novel CAMSAP3 calmodulin regulated spectrin associated protein family member 3
Novel CASP3 caspase 3
  • Activation of caspases through apoptosome-mediated cleavage
  • SMAC (DIABLO) binds to IAPs
  • SMAC(DIABLO)-mediated dissociation of IAP:caspase complexes
  • Apoptotic cleavage of cellular proteins
  • SMAC, XIAP-regulated apoptotic response
  • Apoptosis induced DNA fragmentation
  • Degradation of the extracellular matrix
  • Signaling by Hippo
  • NADE modulates death signalling
  • Stimulation of the cell death response by PAK-2p34
  • Caspase-mediated cleavage of cytoskeletal proteins
  • Apoptotic cleavage of cell adhesion proteins
  • Caspase activation via Dependence Receptors in the absence of ligand
  • Caspase activation via Dependence Receptors in the absence of ligand
  • Other interleukin signaling
  • Pyroptosis
  • CASP4-mediated substrate cleavage
  • CASP5-mediated substrate cleavage
  • Pamidronic acid
  • Acetylsalicylic acid
  • Minocycline
  • 5-[4-(1-Carboxymethyl-2-Oxo-Propylcarbamoyl)-Benzylsulfamoyl]-2-Hydroxy-Benzoic Acid
  • Emricasan
  • Incadronic acid
  • 2-HYDROXY-5-(2-MERCAPTO-ETHYLSULFAMOYL)-BENZOIC ACID
  • methyl (3S)-3-[(tert-butoxycarbonyl)amino]-4-oxopentanoate
  • 1-METHYL-5-(2-PHENOXYMETHYL-PYRROLIDINE-1-SULFONYL)-1H-INDOLE-2,3-DIONE
  • [N-(3-dibenzylcarbamoyl-oxiranecarbonyl)-hydrazino]-acetic acid
  • 4-[5-(2-CARBOXY-1-FORMYL-ETHYLCARBAMOYL)-PYRIDIN-3-YL]-BENZOIC ACID
  • (1S)-2-oxo-1-phenyl-2-[(1,3,4-trioxo-1,2,3,4-tetrahydroisoquinolin-5-yl)amino]ethyl acetate
  • (1S)-1-(3-chlorophenyl)-2-oxo-2-[(1,3,4-trioxo-1,2,3,4-tetrahydroisoquinolin-5-yl)amino]ethyl acetate
  • N-[3-(2-fluoroethoxy)phenyl]-N'-(1,3,4-trioxo-1,2,3,4-tetrahydroisoquinolin-6-yl)butanediamide
  • Tributyrin
  • Oleandrin
  • PAC-1
  • Glycyrrhizic acid
Novel CAV1 caveolin 1
  • Triglyceride catabolism
  • eNOS activation
  • NOSTRIN mediated eNOS trafficking
  • Thyroxine biosynthesis
  • Basigin interactions
  • Disassembly of the destruction complex and recruitment of AXIN to the membrane
  • VEGFR2 mediated vascular permeability
  • RHOA GTPase cycle
  • Extra-nuclear estrogen signaling
  • RHOB GTPase cycle
  • RHOC GTPase cycle
  • CDC42 GTPase cycle
  • RAC1 GTPase cycle
  • RAC2 GTPase cycle
  • RHOD GTPase cycle
  • RHOQ GTPase cycle
  • RHOH GTPase cycle
  • RHOG GTPase cycle
  • RHOJ GTPase cycle
  • RAC3 GTPase cycle
  • RHOF GTPase cycle
  • FOXO-mediated transcription of cell cycle genes
  • RND3 GTPase cycle
  • RND2 GTPase cycle
  • RND1 GTPase cycle
  • SARS-CoV-1 targets host intracellular signalling and regulatory pathways
  • SARS-CoV-2 targets host intracellular signalling and regulatory pathways
  • Congenital generalized lipodystrophy (CGL)
Novel CBL Cbl proto-oncogene
  • Interleukin-6 signaling
  • Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants
  • Spry regulation of FGF signaling
  • Regulation of KIT signaling
  • EGFR downregulation
  • TGF-beta receptor signaling activates SMADs
  • Constitutive Signaling by EGFRvIII
  • Negative regulation of FGFR1 signaling
  • Negative regulation of FGFR2 signaling
  • Negative regulation of FGFR3 signaling
  • Negative regulation of FGFR4 signaling
  • Negative regulation of MET activity
  • PTK6 Regulates RTKs and Their Effectors AKT1 and DOK1
  • Cargo recognition for clathrin-mediated endocytosis
  • Clathrin-mediated endocytosis
  • InlB-mediated entry of Listeria monocytogenes into host cell
  • InlB-mediated entry of Listeria monocytogenes into host cell
  • Regulation of signaling by CBL
  • Regulation of signaling by CBL
  • Signaling by CSF1 (M-CSF) in myeloid cells
  • Negative regulation of FLT3
  • FLT3 signaling by CBL mutants
  • Noonan syndrome and related disorders, including: Noonan syndrome (NS); Leopard syndrome (LS); Noonan syndrome-like with loose anagen hair (NS/LAH); CBL-mutation associated syndrome (CBL); Neurofibromatosis type 1 (NF1); Neurofibromatosis type 2 (NF2); Neurofibromatosis-Noonan syndrome (NFNS); Legius syndrome; Cardiofaciocutaneous syndrome (CFCS); Costello syndrome (CS)
Novel CCND2 cyclin D2
  • Cyclin D associated events in G1
  • Regulation of RUNX1 Expression and Activity
  • Defective binding of RB1 mutants to E2F1,(E2F2, E2F3)
  • Drug-mediated inhibition of CDK4/CDK6 activity
  • Testicular cancer
Novel CD44 CD44 molecule (IN blood group)
  • Degradation of the extracellular matrix
  • Cell surface interactions at the vascular wall
  • Hyaluronan metabolism
  • Integrin cell surface interactions
  • Hyaluronan degradation
  • Neutrophil degranulation
  • Interferon gamma signaling
  • Developmental Lineage of Mammary Gland Luminal Epithelial Cells
  • Developmental Lineage of Mammary Gland Myoepithelial Cells
  • Developmental Lineage of Mammary Stem Cells
  • Bivatuzumab
  • Hyaluronic acid
  • Gastric cancer
Novel CDK4 cyclin dependent kinase 4
  • SCF(Skp2)-mediated degradation of p27/p21
  • Oxidative Stress Induced Senescence
  • Senescence-Associated Secretory Phenotype (SASP)
  • Oncogene Induced Senescence
  • RMTs methylate histone arginines
  • Transcriptional regulation of white adipocyte differentiation
  • Cyclin D associated events in G1
  • Ubiquitin-dependent degradation of Cyclin D
  • Ubiquitin-dependent degradation of Cyclin D
  • PTK6 Regulates Cell Cycle
  • Transcriptional regulation by RUNX2
  • Meiotic recombination
  • Transcriptional regulation of granulopoiesis
  • Evasion of Oncogene Induced Senescence Due to Defective p16INK4A binding to CDK4
  • Evasion of Oncogene Induced Senescence Due to Defective p16INK4A binding to CDK4 and CDK6
  • Evasion of Oxidative Stress Induced Senescence Due to Defective p16INK4A binding to CDK4
  • Evasion of Oxidative Stress Induced Senescence Due to Defective p16INK4A binding to CDK4 and CDK6
  • Defective binding of RB1 mutants to E2F1,(E2F2, E2F3)
  • Drug-mediated inhibition of CDK4/CDK6 activity
  • SPOP-mediated proteasomal degradation of PD-L1(CD274)
  • Purvalanol
  • Alvocidib
  • Palbociclib
  • Ribociclib
  • Abemaciclib
  • Fostamatinib
  • Trilaciclib
  • Malignant melanoma
  • Glioma
  • Cervical cancer
Novel CDK6 cyclin dependent kinase 6
  • Oxidative Stress Induced Senescence
  • Senescence-Associated Secretory Phenotype (SASP)
  • Oncogene Induced Senescence
  • Cyclin D associated events in G1
  • Regulation of RUNX1 Expression and Activity
  • Evasion of Oncogene Induced Senescence Due to Defective p16INK4A binding to CDK4 and CDK6
  • Evasion of Oxidative Stress Induced Senescence Due to Defective p16INK4A binding to CDK4 and CDK6
  • Defective binding of RB1 mutants to E2F1,(E2F2, E2F3)
  • Drug-mediated inhibition of CDK4/CDK6 activity
  • Alvocidib
  • (2S)-2-({6-[(3-Amino-5-chlorophenyl)amino]-9-isopropyl-9H-purin-2-yl}amino)-3-methyl-1-butanol
  • Fisetin
  • Palbociclib
  • Ribociclib
  • Abemaciclib
  • Trilaciclib
Novel CDKN2B cyclin dependent kinase inhibitor 2B
  • SMAD2/SMAD3:SMAD4 heterotrimer regulates transcription
  • Oxidative Stress Induced Senescence
  • Senescence-Associated Secretory Phenotype (SASP)
  • Oncogene Induced Senescence
  • Cyclin D associated events in G1
  • Type II diabetes mellitus
  • Osteosarcoma
  • Malignant pleural mesothelioma
Novel CNR1 cannabinoid receptor 1
  • Class A/1 (Rhodopsin-like receptors)
  • G alpha (i) signalling events
  • Dronabinol
  • Nabilone
  • Ricinoleic acid
  • SLV319
  • V24343
  • AVE-1625
  • Rimonabant
  • Cannabidiol
  • Propacetamol
  • Otenabant
  • Tetrahydrocannabivarin
  • Medical Cannabis
  • Nabiximols
Novel CRK CRK proto-oncogene, adaptor protein
  • ARMS-mediated activation
  • ARMS-mediated activation
  • Downstream signal transduction
  • Regulation of actin dynamics for phagocytic cup formation
  • p130Cas linkage to MAPK signaling for integrins
  • VEGFA-VEGFR2 Pathway
  • PTK6 Regulates RHO GTPases, RAS GTPase and MAP kinases
  • MET activates RAP1 and RAC1
  • MET receptor recycling
  • Regulation of signaling by CBL
  • FCGR3A-mediated phagocytosis
Novel CTNNB1 catenin beta 1
  • Degradation of beta-catenin by the destruction complex
  • Beta-catenin phosphorylation cascade
  • TCF dependent signaling in response to WNT
  • Formation of the beta-catenin:TCF transactivating complex
  • Formation of the beta-catenin:TCF transactivating complex
  • LRR FLII-interacting protein 1 (LRRFIP1) activates type I IFN production
  • Apoptotic cleavage of cell adhesion proteins
  • Deactivation of the beta-catenin transactivating complex
  • Synthesis, secretion, and inactivation of Glucagon-like Peptide-1 (GLP-1)
  • Ca2+ pathway
  • Adherens junctions interactions
  • Binding of TCF/LEF:CTNNB1 to target gene promoters
  • Disassembly of the destruction complex and recruitment of AXIN to the membrane
  • Disassembly of the destruction complex and recruitment of AXIN to the membrane
  • VEGFR2 mediated vascular permeability
  • Myogenesis
  • Myogenesis
  • Signaling by GSK3beta mutants
  • CTNNB1 S33 mutants aren't phosphorylated
  • CTNNB1 S37 mutants aren't phosphorylated
  • CTNNB1 S45 mutants aren't phosphorylated
  • CTNNB1 T41 mutants aren't phosphorylated
  • RHO GTPases activate IQGAPs
  • Transcriptional Regulation by VENTX
  • InlA-mediated entry of Listeria monocytogenes into host cells
  • RUNX3 regulates WNT signaling
  • Cardiogenesis
  • Germ layer formation at gastrulation
  • Regulation of CDH11 function
  • Regulation of CDH11 function
  • Regulation of CDH19 Expression and Function
  • Regulation of CDH1 Function
  • Degradation of CDH1
  • Regulation of CDH1 posttranslational processing and trafficking to plasma membrane
  • Formation of paraxial mesoderm
  • Formation of axial mesoderm
  • Formation of definitive endoderm
  • Somitogenesis
  • Regulation of MITF-M-dependent genes involved in pigmentation
  • Regulation of MITF-M-dependent genes involved in cell cycle and proliferation
  • Formation of the nephric duct
  • CDH11 homotypic and heterotypic interactions
  • Specification of the neural plate border
  • High laminar flow shear stress activates signaling by PIEZO1 and PECAM1:CDH5:KDR in endothelial cells
  • Transcriptional and post-translational regulation of MITF-M expression and activity
  • Regulation of PD-L1(CD274) transcription
  • Urea
  • Pilomatricoma; Epithelioma calcificans of Malherbe
  • Gastric cancer
  • Hepatocellular carcinoma
  • Thyroid cancer
  • Colorectal cancer
  • Endometrial Cancer
Novel CTTN cortactin
  • RHO GTPases activate PAKs
  • Clathrin-mediated endocytosis
Novel DAPK3 death associated protein kinase 3
  • Caspase activation via Dependence Receptors in the absence of ligand
  • 2-tert-butyl-9-fluoro-1,6-dihydrobenzo[h]imidazo[4,5-f]isoquinolin-7-one
  • 4-(6-{[(1R)-1-(hydroxymethyl)propyl]amino}imidazo[1,2-b]pyridazin-3-yl)benzoic acid
  • (4R)-7,8-dichloro-1',9-dimethyl-1-oxo-1,2,4,9-tetrahydrospiro[beta-carboline-3,4'-piperidine]-4-carbonitrile
  • Fostamatinib
Novel DCN decorin
  • Degradation of the extracellular matrix
  • Glycosaminoglycan-protein linkage region biosynthesis
  • CS-GAG biosynthesis
  • DS-GAG biosynthesis
  • CS/DS degradation
  • ECM proteoglycans
  • ECM proteoglycans
  • Defective B4GALT7 causes EDS, progeroid type
  • Defective B3GAT3 causes JDSSDHD
  • Defective CHST3 causes SEDCJD
  • Defective CHST14 causes EDS, musculocontractural type
  • Defective CHSY1 causes TPBS
  • Defective B3GALT6 causes EDSP2 and SEMDJL1
  • Congenital stromal corneal dystrophy (CSCD); Congenital hereditary stromal dystrophy; Witschel dystrophy

Page 1 out of 13 pages